Company Overview
Company Type: Private Company
Website: microbiomeinsights.com
Number of Employees: -
Year Founded: 2015
Total Amount Raised (CAD mm)†: 0.40
Total Rounds of Funding**:4
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Microbiome Insights Inc. provides microbiome analysis and testing services for academic and industrial researchers in Canada. The company primarily focuses on communities of microbial cells, including bacteria, viruses, and fungi that inhabit humans, animals, plants, and environment. It enables researchers and clinicians to include microbiome analysis in their studies across a range of human, animal, agricultural, and environmental research applications. The company’s services include quantitation of microbial populations or groups of interest; analysis of combined genetic potential of microbial communities; and analysis of combined gene expression of microbial communities. Microbiome Insights Inc. was incorporated in 2015 and is based in Richmond, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Kendall, Malcolm 
CEO & Director
Finlay, B. Brett
Co-Founder, Co-CSO and Director
Mohn, Bill 
Co-Founder, Co-CSO and Director
Liggett, Michael 
Consulting Chief Financial Officer
Gandhi, Anusha
Senior Director of Sales and Business Development

Key Board Members
Name
Title
Kendall, Malcolm 
CEO & Director
Finlay, B. Brett
Co-Founder, Co-CSO and Director
Mohn, Bill 
Co-Founder, Co-CSO and Director
Buchanan, Doug 
Director
Cullis, Pieter R.
Independent Director
Enns, Don M.
Independent Director
Fannon, Mike
Independent Director
Popovich, Bradley
Independent Director


Primary Industry Classification
Research and Consulting Services


Primary Office Location
13520 Crestwood Place Unit 12 | Richmond, BC | V6V 2G3 | Canada
Phone: 604-356-4228   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Genome British Columbia
Oct-31-2017
Minority
-
Venture


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jan-25-2019
Mar-27-2019
Private Placement
Target
Microbiome Insights Inc.


0.12
Oct-31-2017
Dec-06-2017
Private Placement
Target
Microbiome Insights Inc.
Genome British Columbia

-
Aug-01-2017
Aug-16-2017
Private Placement
Target
Microbiome Insights Inc.


0.17
Sep-23-2015
Nov-10-2015
Private Placement
Target
Microbiome Insights Inc.


0.02
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
May-23-2023
Company Conference Presentations
Microbiome Insights Inc. Presents at Microbiome & Probiotic R&D & Business Collaboration Forum: Europe 2023, May-23-2023
Nov-03-2021
Company Conference Presentations
Microbiome Insights Inc. Presents at 6th Annual Invest in BC, Nov-03-2021
Jul-23-2019
Executive/Board Changes - Other
Doug Buchanan Joins the Microbiome Insights's Board of Directors
Jun-18-2019
Executive/Board Changes - Other
Microbiome Insights, Inc. Announces the Appointment of Don Enns as an Independent Member to its Board of Directors
Mar-27-2019
Private Placements
Microbiome Insights Inc. announced that it has received $0.115978 million in funding

Competitors
CoreBiome, Inc., CosmosID, Inc., Eagle Genomics Ltd., Microba Life Sciences Limited (ASX:MAP)


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Bioinformaticians

Key Board Members Details
Name
Title
Phone
Fax
Email
Kendall, Malcolm 
CEO & Director
(604) 551-8464
-
mkendall@indelrx.com
Finlay, B. Brett
Co-Founder, Co-CSO and Director
604-356-4228
-

Mohn, Bill 
Co-Founder, Co-CSO and Director
604-356-4228
-

Buchanan, Doug 
Director
604-356-4228
-
-
Cullis, Pieter R.
Independent Director
604-356-4228
-
-
Enns, Don M.
Independent Director
604-356-4228
-

Fannon, Mike
Independent Director
604-356-4228
-
-
Popovich, Bradley
Independent Director
604-356-4228
-
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Kendall, Malcolm 
CEO & Director
(604) 551-8464
-
mkendall@indelrx.com
Finlay, B. Brett
Co-Founder, Co-CSO and Director
604-356-4228
-

Mohn, Bill 
Co-Founder, Co-CSO and Director
604-356-4228
-

Liggett, Michael 
Consulting Chief Financial Officer
(778) 802-9806
-
liggett@icotherapeutics.com.
Gandhi, Anusha
Senior Director of Sales and Business Development
604-356-4228
-
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
